AzTrials
AzTrials

Cirrhosis, LiverNCT05059795

Volume Resuscitation in Cirrhosis With Sepsis Induced Hypotension

An observational study of Cirrhosis, Liver and Sepsis, run by Post Graduate Institute of Medical Education and Research, Chandigarh at 2 sites in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In critically ill patients with liver disease like cirrhosis or ACLF, fluid therapy needs to be instituted after identification of patients who will be fluid responsive and initiate appropriate inotropes early to prevent the mortality associated with fluid overload. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Albumin + electrolyte solution and POCUS guided fluid resuscitation
How many people
350 participants
Where
2 sitesIndia
Study dates
1 Feb 2020to 10 Aug 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients 18-65 years age with cirrhosis of any etiology now presenting with sepsis induced hypotension

Who may be able to join

  • Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology
  • Hypotension (MAP <65mmHg or SBP <90mmHg)
  • 18-65 yrs of age

Who cannot join

  • Already received colloid or 2 litres of fluid within the first 2 hours of presentation, without echocardiographic assessment.
  • Already on vasopressors/inotropes
  • Severe pre-existing cardiopulmonary disease
  • Acute Respiratory Distress Syndrome (ARDS)
  • Active bleeding like variceal bleed 28
  • Cerebrovascular events
Show all 12Show fewer
  • Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
  • Admission to ICU following liver transplantation, burns, cardiac surgery
  • Brain death or likely brain death within 24 hours
  • Previous adverse reaction to human albumin solution
  • Pregnant or lactating women
  • Informed consent refused by patient or attendants

Trial locations and contacts

2 sites in 1 country.

India2 sites
  • PGIMER

    Chandigarh, Chandigarh, 160012

  • Postgraduate Institute of Medical Education and Research

    Chandigarh, 160012

Other trials in India

About this study

Official title: To Compare the Effectiveness of Various Methods of Estimating Volume Resuscitation in Patients With Cirrhosis With Sepsis Induced Hypotension

In critically ill patients with liver disease like cirrhosis or ACLF, fluid therapy needs to be instituted after identification of patients who will be fluid responsive and initiate appropriate inotropes early to prevent the mortality associated with fluid overload.

The parameters and methodology used for assessing fluid responsiveness have been studied earlier, but the optimum method is not established. Existing recommendations based on data regarding fluid responsiveness and choice of fluid for resuscitation from intensive care units in general cannot be applied to those with liver disease as the hemodynamic alterations that occur with liver disease, presence of hypoalbuminemia at baseline and presence of cardiac dysfunction interfere with the conventional methods of fluid status assessment, fluid responsiveness as well as the response to different types of resuscitation fluids.

Therefore the investigators attempt to compare various methods to estimate current intravascular volume status of patient which could be helpful in guiding fluid therapy.

Read the detailed description

Objectives:

  1. To compare the accuracy of central venous pressure and inferior vena cava dynamic assessment and lactate clearance for estimating adequacy of fluid resuscitation in patients with cirrhosis with sepsis induced hypotension .[Time Frame at enrolment, 6 hours, 24 hours]
  2. Predictors of all-cause mortality at Day 7 and day 28. [Time Frame Day 7 and Day 28]

PATIENTS AND METHODS Study Design: A Prospective observational study

Case Definition:

Cirrhosis will be defined by - "clinical features consistent with chronic liver disease (CLD) including a consistent history as well as a documented complication of CLD (i.e., ascites, varices, hepatic encephalopathy) and/or imaging results consistent with cirrhosis and/or liver histologic findings consistent with cirrhosis" ACLF will be defined as per EASL criteria with documentation of organ failures.

Systemic Inflammatory Response Syndrome (SIRS) - 2 more of following 4

  1. Oral temperature >38.3oC or <36oC
  2. Heart Rate > 90 beats/min
  3. Respiratory Rate >20 breaths/min or PaCO2 <32mmHg
  4. WBC count >12000/cumm, <4000/cumm or >10% immature band forms Sepsis is a SIRS in response to proven or suspected microbial event 'Sepsis induced hypotension' implies mean arterial pressure < 65 mmHg or a reduction of >40 mm Hg from baseline in the absence of other causes of hypotension Severe sepsis - sepsis-induced tissue hypoperfusion or organ dysfunction (any of the following thought to be due to the infection)
  • Sepsis-induced hypotension
  • Lactate above upper limits laboratory normal
  • Urine output < 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation
  • Acute lung injury with PaO2/FIO2 < 250 in the absence of pneumonia as infection source
  • Acute lung injury with PaO2/FIO2 < 200 in the presence of pneumonia as infection source
  • Creatinine > 2.0 mg/dL (176.8 μmol/L)
  • Bilirubin > 2 mg/dL (34.2 μmol/L)
  • Platelet count < 100,000 μL
  • Coagulopathy (international normalized ratio > 1.5) Septic shock is "sepsis induced hypotension despite adequate fluid resuscitation along with organ dysfunction or perfusion abnormality".

Acute kidney injury (AKI) is defined as any of the following:

  1. Increase in SCr by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 hours; or
  2. Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
  3. Urine volume <0.5 ml/kg/h for 6 hours

Definition of Adequate Intravascular volume - IVC diameter ≥ 18mm and IVCCI <40% Definition of Adequate fluid resuscitation - Achieving MAP ≥ 65mmHg with Fluid bolus

All patients eligible for the study will undergo screening as per the above criteria. The ones who satisfy the criteria will be counselled for participation in the study and written informed consent will be taken from the patient / the legal guardian in patients who are unable to do so. Patient information sheets will also be signed, briefing the patients about why the research work is necessary and also about the methodology.

Detail history and clinical examination will be done in all cases and the findings along with all investigation results will be recorded in a standard case record form. Information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, demographic characteristics, routine biochemical and hematological investigations.

  • After enrolment, baseline samples would be taken for routine investigations and samples for evaluation of sepsis - blood culture, urine culture, fluid cultures, procalcitonin will be taken.
  • The patient would be assessed for 5 parameters and will be reassessed 30min and 4hours after starting fluid resuscitation.
  1. IVC diameter and collapsibility Index
  2. Serum lactate levels
  3. Venous-arterial pCO2 difference
  4. CVP where central line inserted as per treating physician's decision
  5. ScVO2 where central line available
  • The patients in septic shock where IVC diameter <18mm or IVCCI≥40% in spontaneously breathing patients, would be regarded in fluid depleted state and will be given aggressive fluid resuscitation with 20% albumin 100 ml started within 30 min which is a standard fluid of choice in patients with cirrhosis and other fluids - Normal Saline/ balanced salt solution 30ml/kg over 3hrs. (The patients who not fulfil above criteria would be assumed in a fluid replete state and be started on maintenance fluid management along with inotrope support as per standard dosage guidelines) Norepinephrine would be 1st choice vasopressor - started at a dose of 4μg/min and titrated every 20 min to a maximum of 21.3μg/min. If MAP still <65mmHg, Vasopressor would be added starting from a 0.01U/min to 0.04U/min. Adrenaline would be added in shock refractory to both vasopressors in dose of 4-24μg/min.
  • Along with fluid and inotrope support, the patient will also receive standard of care including empiric broad spectrum antibiotics, oxygen support/ventilator support if needed.
  • MAP would be rechecked 30 min after starting fluid therapy. IVC diameter and IVCCI would also be checked at same time to see if change in MAP (if any) is reflected in the IVC status. Adequate fluid resuscitation would be defined by achieving a MAP ≥ 65mmHg. In patients achieving MAP≥65mmHg, fluid therapy will be continued. The patients still having MAP<65 mmHg will be started on inotrope support according to standard guidelines.
  • IVC, IVCCI, Lactate, venous-arterial pCO2 difference, CVP and ScVO2 would be remeasured at 4 hrs.
  • The patient would be the followed with serial examinations, calculations of SOFA score, CTP and MELD.
  • Samples to test for sepsis such as procalcitonin, galactomannan, beta D Glucan and high sensitivity CRP will be done every 48-72 hours as determined by the treating clinician.
  • Cultures for bacterial and fungal sepsis will be taken as per the Liver ICU protocol.
  • If discharged earlier, for the purpose of 28-day mortality the patients' kin would be contacted telephonically.
  • Data regarding total amount of fluids, type of fluids, urine output, dose and duration of inotropes, initiation of RRT, total days in ICU/Hospital, immediate cause of death (In case of mortality) would be noted.

Presence of Cirrhotic Cardiomyopathy as per updated 2020 CCMC criteria.

CCM is defined as systolic or diastolic dysfunction in the absence of alternative cardiac pathology in concordance with the Cirrhotic Cardiomyopathy Consortium (CCMC) criteria. 9 Systolic dysfunction was defined as an ejection fraction (EF) ≤50% or an absolute value of GLS <18%. LVDD will be defined as presence of 3 of the following 4 criteria: septal early diastolic mitral annular flow velocity (e') <7 cm/s, early diastolic transmitral flow to early diastolic mitral annular velocity (E/e') ≥15, left atrial volume index (LAVI) >34 mL/m2, tricuspid jet maximum velocity >2.8 m/s, in the absence of pulmonary hypertension and the presence of measurable early to late diastolic transmitral flow velocity (E/A) ratio (E/A >2 = grade 3 \& E/A 0.8-2 = grade 2 LVDD). Persons meeting only 2 criteria will be termed as indeterminate for LVDD grade. 19

Being tested
Albumin + electrolyte solution, POCUS guided fluid resuscitation
Keywords
Resuscitation in cirrhosis, Inferior vena cava dynamics, Central Venous Pressure in cirrhosis, Lactate clearance in cirrhosis, Acute-on-chronic liver failure, Sepsis in Cirrhosis, Shock in ACLF and Cirrhosis
Medical subject headings
Liver Cirrhosis, Sepsis, Acute-On-Chronic Liver Failure, Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Albumin + electrolyte solutionDrug

    Also called Crystalloid

    Type of resuscitation fluid, dose and use of inotrope

  • POCUS guided fluid resuscitationDiagnostic test

    Conventional goal directed therapy

Study groups in NCT05059795
Study groupRoleWhat they receive
Cirrhosis/ACLF of any etiologyNot described
Receives: Drug: Albumin + electrolyte solution; Diagnostic Test: POCUS guided fluid resuscitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Achievement of Mean Arterial pressure >65 mmHg

    Measured: At the end of 4 hours since admission (time zero)

Secondary outcomes (29)
  1. Requirement of vasopressors

    Measured: At the end of 4 hours of admission

  2. Requirement of vasopressors

    Measured: At the end of 24 hours of admission

  3. Volume of fluid infused

    Dose of albumin

    Measured: At the end of 4 hours of admission

  4. Volume of fluid infused

    Dose of crystalloid

    Measured: At the end of 24 hours of admission

  5. Volume of fluid infused

    Total volume of fluids

    Measured: At the end of 36 hours of admission

  6. Volume of fluid infused

    Dose of albumin and crystalloid

    Measured: At the end of 48 hours of admission

  7. Volume of fluid infused

    Dose of albumin and crystalloid

    Measured: At the end of 72 hours of admission

  8. Incidence of Acute Kidney Injury

    Measured: At admission

  9. Incidence of Acute Kidney Injury

    Any new episode of AKI documented in the first week of admission

    Measured: Day 7

  10. Incidence of new organ dysfunction (encephalopathy, coagulation failure, respiratory failure)

    Any new episode of new organ dysfunction documented in the first week of admission

    Measured: Day 7

  11. Duration of ICU stay

    The total duration of stay in intensive care, which will be assessed till 28 days

    Measured: Total duration of ICU stay in days

  12. Duration of hospital stay

    The total duration of stay in hospital, which will be assessed till 28 days

    Measured: Total duration of admission as a hospital inpatient, assessed till 28 days

  13. Mortality

    Incidence of death at the end of 1 week i.e. early mortality

    Measured: Day 7

  14. Mortality

    Incidence of death at the end of 4 weeks i.e. late mortality

    Measured: Day 28

  15. Documentation of Cardiac index

    POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1

    Measured: Time zero at admission

  16. Documentation of Cardiac index at 6h

    POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1

    Measured: At 6 hours of admission

  17. Documentation of Cardiac index at 24h

    POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1

    Measured: At 24 hours of admission

  18. Documentation of Cardiac index at 48h

    POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1

    Measured: At 48 hours of admission

  19. Documentation of Cardiac index at 72h

    POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1

    Measured: At 72 hours of admission

  20. Documentation of POCUS systemic vascular resistance index

    POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: Time zero at admission

  21. Documentation of POCUS systemic vascular resistance index at 6h

    POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: at 6hours of admission

  22. Documentation of POCUS systemic vascular resistance index at 24h

    POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: at 24hours of admission

  23. Documentation of POCUS systemic vascular resistance index at 48h

    POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: at 48hours of admission

  24. Documentation of POCUS systemic vascular resistance index at 72h

    POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: at 72hours of admission

  25. Documentation of IVC dynamics

    POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: time zero at admission (Day 0)

  26. Documentation of IVC dynamics

    POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: At 6hours of admission (Day 1)

  27. Documentation of IVC dynamics

    POC ultrasound and echocardiography documentation for changes in echo parameters (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: at 24hours of admission

  28. Documentation of IVC dynamics

    POC ultrasound and echocardiography documentation for changes in echo parameters (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: at 48hours of admission

  29. Documentation of IVC dynamics

    POC ultrasound and echocardiography documentation for changes in echo parameters (Cardiac index), Systemic Vascular resistance index (SVRI)

    Measured: at 72hours of admission

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Sep 2021
  2. Study start1 Feb 2020
  3. Primary completion1 Jul 2025
  4. Study completion10 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
350 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05059795
Sponsor's protocol ID
Im/2019/2917
Status last verified
Aug 2025
First submitted
4 Jul 2020
Last updated
2 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, Vauquelin P, Assous M, Sicot C. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med. 1992 Jun;20(6):746-50. doi: 10.1097/00003246-199206000-00008.

    PubMed 1597026
  • ARISE Investigators; ANZICS Clinical Trials Group; Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16;371(16):1496-506. doi: 10.1056/NEJMoa1404380. Epub 2014 Oct 1.

    PubMed 25272316
  • Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008 Jul;134(1):172-8. doi: 10.1378/chest.07-2331.

    PubMed 18628220
  • Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? JAMA. 2016 Sep 27;316(12):1298-309. doi: 10.1001/jama.2016.12310.

    PubMed 27673307
  • Velissaris D, Pierrakos C, Scolletta S, De Backer D, Vincent JL. High mixed venous oxygen saturation levels do not exclude fluid responsiveness in critically ill septic patients. Crit Care. 2011 Jul 26;15(4):R177. doi: 10.1186/cc10326.

    PubMed 21791090
  • Lee YK, Hwang SY, Shin TG, Jo IJ, Suh GY, Jeon K. Prognostic Value of Lactate and Central Venous Oxygen Saturation after Early Resuscitation in Sepsis Patients. PLoS One. 2016 Apr 7;11(4):e0153305. doi: 10.1371/journal.pone.0153305. eCollection 2016.

    PubMed 27054713
  • Lee J, de Louw E, Niemi M, Nelson R, Mark RG, Celi LA, Mukamal KJ, Danziger J. Association between fluid balance and survival in critically ill patients. J Intern Med. 2015 Apr;277(4):468-77. doi: 10.1111/joim.12274. Epub 2014 Jun 27.

    PubMed 24931482
  • Sefidbakht S, Assadsangabi R, Abbasi HR, Nabavizadeh A. Sonographic measurement of the inferior vena cava as a predictor of shock in trauma patients. Emerg Radiol. 2007 Jul;14(3):181-5. doi: 10.1007/s10140-007-0602-4. Epub 2007 Jun 1.

    PubMed 17541661
  • Premkumar M, Rangegowda D, Kajal K, Khumuckham JS. Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography. JGH Open. 2019 Mar 12;3(4):322-328. doi: 10.1002/jgh3.12166. eCollection 2019 Aug.

    PubMed 31406926
  • Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J; LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010 Sep 15;182(6):752-61. doi: 10.1164/rccm.200912-1918OC. Epub 2010 May 12.

    PubMed 20463176
  • Du W, Liu DW, Wang XT, Long Y, Chai WZ, Zhou X, Rui X. Combining central venous-to-arterial partial pressure of carbon dioxide difference and central venous oxygen saturation to guide resuscitation in septic shock. J Crit Care. 2013 Dec;28(6):1110.e1-5. doi: 10.1016/j.jcrc.2013.07.049.

    PubMed 24216336
  • Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020 Jan;71(1):334-345. doi: 10.1002/hep.30875. Epub 2019 Oct 11.

    PubMed 31342529

Questions about this trial

What is this clinical trial studying?

An observational study of Cirrhosis, Liver and Sepsis, run by Post Graduate Institute of Medical Education and Research, Chandigarh at 2 sites in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Achievement of Mean Arterial pressure >65 mmHg (time frame: At the end of 4 hours since admission (time zero)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05059795, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in